poisar

Stocks · News reference

Concentrix Posts Mixed Q3 Results, Joins Cal-Maine Foods And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

BenzingaAvi Kapoor

Concentrix plunged 10.6% premarket after weak guidance, despite an earnings beat; several other stocks also traded lower.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncDelveinsight

    NSCLC Treatment Landscape Shifts as ESMO 2026 Spotlights MET, KRAS, and TROP2 Advances, Says DelveInsight

    The non-small cell lung cancer market is shifting toward precision, biomarker-guided treatment sequencing. ESMO 2026 presented Phase III data showing savolitinib plus osimertinib improved survival in MET-altered EGFR-mutated NSCLC, divarasib outperformed approved KRAS G12C inhibitors, and TROP2-directed ADCs demonstrated durable gains. The 7MM NSCLC market is projected to double from USD 33 billion in 2025 to USD 67 billion by 2036, driven by expanded screening, biomarker-driven therapies, and label expansions into earlier-stage disease.

  2. The Motley FoolTrevor Jennewine

    Should You Really Buy Anthropic Stock At the IPO? History Has a Clear Answer for Investors.

    Anthropic is set to go public on November 19, 2026, at a $1.33 trillion valuation with a proposed IPO price of $70-$78 per share. While the company shows explosive revenue growth (12-fold increase to $17B in Q3), its 38x price-to-sales valuation is expensive. Historical data shows the 10 largest U.S. IPOs since 2006 declined an average of 32% from their IPO price within the first year, suggesting investors should wait for better entry points rather than buying at the IPO.

  3. Globenewswire IncDelveinsight

    Cancer Vaccines Clinical Trial Pipeline Boom as 200+ Companies are in the Race for Better Treatments | DelveInsight

    Over 200 companies are advancing cancer vaccine development with 200+ pipeline candidates in clinical trials. Recent positive Phase III results for intismeran autogene (mRNA-4157) in melanoma and encouraging data for TG4050 in head and neck cancer are driving momentum. However, challenges including clinical efficacy uncertainties, manufacturing complexity, high production costs, and patient selection barriers remain obstacles to broader commercialization.